🇺🇸 FDA
Pipeline program

TRASTUZUMAB, Tislelizumab, Oxaliplatin 5 mg/ml concentrate for solution for infusion, LOPERAMIDE, JZP598, CAPECITABINE

ZWI-ZW25-301

Phase 3 small_molecule active

Quick answer

TRASTUZUMAB, Tislelizumab, Oxaliplatin 5 mg/ml concentrate for solution for infusion, LOPERAMIDE, JZP598, CAPECITABINE for Gastroesophageal Adenocarcinoma (GEA) is a Phase 3 program (small_molecule) at Jazz Pharmaceuticals Ireland Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Jazz Pharmaceuticals Ireland Limited
Indication
Gastroesophageal Adenocarcinoma (GEA)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials